French-Belgian medtech company NeuroClues has raised €10 million to support the early diagnosis of Parkinson's, Alzheimer's, and multiple sclerosis. The company uses a portable headset to capture up to 800 infrared images per eye per second, which can indicate neurological disorders years before clinical symptoms appear. NeuroClue received CE certification for its Class IIa medical device in January 2025, allowing it for use in the European market. This brings its total funding raised since its founding in 2020 to over €22 million. The new capital will be used to build out the commercial team, pursue FDA clearance in the United States in 2026, and expand into European markets.